Skip to main content
SpringerLink
Log in

Dalbavancin in acute bacterial skin infections saves costs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was supported by an unconditional grant from Angelini SpA.

Reference

  • Marcellusi A, et al. Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries. Clinical Drug Investigation : 7 Feb 2020. Available from: URL: https://doi.org/10.1007/s40261-020-00891-w

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dalbavancin in acute bacterial skin infections saves costs. PharmacoEcon Outcomes News 847, 9 (2020). https://doi.org/10.1007/s40274-020-6585-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6585-z

Search

Navigation